Meprobamate

Summary

Meprobamate (CHEMBL979) is an approved small molecule (ATC N05BC01); indicated across 2 conditions including anxiety.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05BC01 (+2 more)
• Indications: 2 conditions
• Chemistry: 218.25 Da · C9H18N2O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL979
Name	Meprobamate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	4064
ATC	N05BC01, N05BC51, N05CX01
Molecular formula	C9H18N2O4
Molecular weight	218.25
InChIKey	NPPQSCRMBWNHMW-UHFFFAOYSA-N

SMILES: CCCC(C)(COC(=O)N)COC(=O)N

IUPAC name: [2-(carbamoyloxymethyl)-2-methylpentyl] carbamate

Also known as: Amosene, Bamate, Equanil, Mepriam, Meprobamate, Meprobamate civ, Meprobamate component of equagesic, Meprobamate component of mepro-aspirin, Meprobamate component of micrainin, Meprobamate component of q-gesic, Meprobamato, Meprospan

Patent coverage: 12,026 distinct patent families (37,239 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Prelamin-A/C, 3-hydroxyacyl-CoA dehydrogenase type-2.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	6.35	Potency	446.7	nM	CHEMBL_ACT_3652108

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
anxiety	4	MONDO:0011918	EFO:0005230
anxiety disorder	4	MONDO:0005618	EFO:0006788

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).